G.A. Dudina1, I.N. Kontievskiy1, V.N. Perova2
1 – Moscow Regional Scientific-Research Clinical Institute n.a. M.F. Vladimirskiy, Moscow, Russian Federation
2 – Municipal Clinical City Hospital, Dubna, Russian Federation
We present clinical case that demonstrates high efficiency of eltrombopag for the treatment of immune thrombocytopenia. It is shown that stable effect may persist after a course of eltrombopag therapy during 2 months. Eltrombopag is highly effective with repeated use.
Keywords: Immune thrombocytopenia, eltrombopag, Revolade.
- Kalota A., Brennan K., Erickson-Miller C.L. et al. Effects of SB559457, a novel small molecule thrombopoietin receptor (TpoR) agonist, on human hematopoietic cell growth and diff erentiation. Blood 2004; 104: 796a (abstr 2913).
- Bussel B., Provan D., Shamsi T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641–8.
- Cheng G., Saleh M.N., Marcher C. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2010; 376: 1–10.
- Bussel J.B., Saleh M.N., Vasey S.Y. et al. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology (http:onlinelibrary.wiley.com/doi/10.1111/bjh.12169/full).